Pfizer study highlights performance of rituximab biosimilar

Pfizer has announced new clinical data affirming the safety and efficacy of its new biosimilar version of rituximab.

Data from REFLECTIONS B3281006, a comparative safety and efficacy study of PF-05280586 versus MabThera, showed that the drug was able to meet its primary endpoint. PF-05280586 is being developed as a potential equivalent to MabThera.

The trial demonstrated equivalence in overall response rate for the first-line treatment of patients with CD20-positive, low-tumour-burden follicular lymphoma.

Dr Amrit Ray, global president for research and development at Pfizer Essential Health, said: "As a global leader in novel biologics, and with one of the broadest global portfolios in oncology, we are delivering on our commitment to advancing high-quality medicines for the millions of patients with cancer around the world today and in the future."

Pfizer's biosimilars pipeline currently consists of seven distinct biosimilar molecules in mid to late-stage development, with three of these in the field of oncology. The company also has a number of other compounds in early-stage development.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.